EyeArt
Eyenuk, Inc is listed for EyeArt (K200667). The FDA list gives August 3, 2020 as the date of the final decision. The lead panel is Ophthalmic, and the database link on the FDA list is the 510(k) pathway. openFDA describes product code PIB as “Diabetic Retinopathy Detection Device”: A retinal diagnostic software device is a prescription software device that incorporates an adaptive algorithm to evaluate ophthalmic images for diagnostic screening to identify retinal diseases or conditions. openFDA records this submission’s decision description as “Substantially Equivalent.” This paragraph is assembled only from those public fields. It is not an FDA review, not a determination of safety or effectiveness, and not medical advice. Official record: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPMN/pmn.cfm?ID=K200667
- Date of final decision
- August 3, 2020
- Company on the FDA list
- Eyenuk, Inc
- Lead panel
- Ophthalmic
- Primary product code
- PIB
- openFDA device name for the code
- Diabetic Retinopathy Detection Device
- Device class
- 2
- Regulation number
- 886.1100
- openFDA decision description
- Substantially Equivalent
- openFDA decision code
- SESE
- Statement or summary label
- Summary
Product-code text from openFDA
A retinal diagnostic software device is a prescription software device that incorporates an adaptive algorithm to evaluate ophthalmic images for diagnostic screening to identify retinal diseases or conditions.